PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers.
about
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective mannerPhosphatome profiling reveals PTPN2, PTPRJ and PTEN as potent negative regulators of PKB/Akt activation in Ras-mutated cancer cellsAdvances in targeted and immunobased therapies for colorectal cancer in the genomic eraDual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal CancersSimilar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistancePersonalized treatment for advanced colorectal cancer: KRAS and beyondImpact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotypeDasatinib sensitizes KRAS mutant colorectal tumors to cetuximabmTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors.Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancerMyricetin induces apoptosis by inhibiting P21 activated kinase 1 (PAK1) signaling cascade in hepatocellular carcinomaPilocytic astrocytoma: a disease with evolving molecular heterogeneityBAY61-3606 affects the viability of colon cancer cells in a genotype-directed mannerDecoupling polarization of the Golgi apparatus and GM1 in the plasma membraneA meta-analysis approach for characterizing pan-cancer mechanisms of drug sensitivity in cell linesPI3K and cancer: lessons, challenges and opportunitiesTranslating genomic profiling to gastrointestinal cancer treatment.Analysis of mRNA profiles after MEK1/2 inhibition in human pancreatic cancer cell lines reveals pathways involved in drug sensitivity.Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors.Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cellsEffective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitorFrom basic research to clinical development of MEK1/2 inhibitors for cancer therapy.Permissiveness of human cancer cells to oncolytic bovine herpesvirus 1 is mediated in part by KRAS activityFGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.Panel based MALDI-TOF tumour profiling is a sensitive method for detecting mutations in clinical non small cell lung cancer tumour.Caffeic acid derivatives inhibit the growth of colon cancer: involvement of the PI3-K/Akt and AMPK signaling pathwaysAntitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.Development, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an in vivo model of childhood astrocytoma.Antitumor activity and pharmacologic characterization of the depsipeptide analog as a novel histone deacetylase/ phosphatidylinositol 3-kinase dual inhibitor.Targeting the cancer kinome through polypharmacology.Activated MEK cooperates with Ink4a/Arf loss or Akt activation to induce gliomas in vivoSelective BRAFV600E inhibitor PLX4720, requires TRAIL assistance to overcome oncogenic PIK3CA resistance.A high-throughput assay for small molecule destabilizers of the KRAS oncoproteinSpontaneous genomic alterations in a chimeric model of colorectal cancer enable metastasis and guide effective combinatorial therapyERBB3 knockdown induces cell cycle arrest and activation of Bak and Bax-dependent apoptosis in colon cancer cells.Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines.RAS Interaction with PI3K: More Than Just Another Effector PathwayInhibition of fatty acid synthase induces pro-survival Akt and ERK signaling in K-Ras-driven cancer cells.
P2860
Q21629049-0CB1B687-9074-4FAC-9E14-BD730B9B8E0CQ24318292-5EF5C56C-4AAC-4966-A04D-0F7DF80E9D95Q26751344-E32D3B99-1004-4360-AD01-5A40A07935A5Q26781362-C0938D32-3373-41EC-9988-A013609CCD91Q26795609-D1069808-FA29-49A7-AB0B-828DBFD4B45CQ26822817-B5F98B3E-06C1-4C3E-BB79-815C4FF19735Q27334924-A132E002-68F2-4083-B20A-3DC67514DCC7Q27851586-FF9BB395-53FF-4A04-A071-70F3484CD025Q27851707-62246B5A-EE04-4CA3-9FD3-A80B15A534E0Q27852623-85A2F8F0-3EC6-4D6B-BC15-8ECCFE5774D3Q27853310-623F53C0-483D-4869-91ED-5F786A7B06EFQ28076490-F3731CBF-E7F4-4D12-988D-28DDBBA676F8Q28263921-293B3E4A-D30C-4958-AEC9-E9C46D49DD2CQ28286218-83927E26-1D5E-4C4E-9589-D20348DC1496Q28481390-C53E1F9F-12CE-4C92-AA94-E6FD2BABF7BEQ28535581-5AC61CE3-37B7-490A-B820-504A0B1DC296Q28540936-71C7F88F-C0FE-4905-91DD-3058863059D8Q30080017-E02F58FE-C535-49BD-8626-0730A4345A25Q30239109-E8D525C4-1046-4555-8BB2-4950D0DC98BBQ30409158-8EC239AA-AC61-42FE-9BFB-805B188A4779Q33439312-36D74CC2-560B-4DB1-AF0F-0E3BCA64379FQ33564297-FB5185B7-0F99-4D94-B376-83BA7D1CF909Q33597663-6B13573A-6EE1-4DEB-93B8-D201B43CFFF8Q33698374-C091790C-6C5F-45AE-9D65-6748087C461AQ33743847-0A5EA001-A939-4AE6-803C-492DE16E929AQ33745140-4CBF9B3B-E20B-494C-9208-6747AD3F1424Q33793611-916FE0CA-3143-40A0-8EEF-C6B8548986B1Q33800268-8BF1D0E6-9F10-49CA-BBD4-2B2320EFE95FQ33820374-66DE9854-03BA-4470-9DFF-B6541968905BQ33861173-AC4CE2ED-CD98-487A-8A73-5B9255FA0171Q33873157-172C561E-8F3A-4FFA-AE2F-390C1869535DQ33893019-EEE12469-2D18-4EF6-A757-A0F5D94926A3Q33945972-2F3B28A8-5AA7-4B15-9108-1E5FDD4F1B42Q33955186-69164CB5-32C7-4BC6-A9EE-568E6433E6F7Q34004748-87134A49-106D-4E6A-8481-ACC29D38D72DQ34097654-31AF4F63-40BD-487F-B7B8-32F0D6A529FFQ34104165-30E842D9-2ADD-41C3-8403-A2F8A396B4BBQ34129528-A8600DCD-28AD-4747-9C84-C6AED76EC8FDQ34202692-214EB34B-8AB3-4AEC-BB2D-F0BA42722BCEQ34223118-ACDFFA1E-6446-4B7A-B1EF-D9EE29CA3287
P2860
PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers.
@en
PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers.
@nl
type
label
PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers.
@en
PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers.
@nl
prefLabel
PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers.
@en
PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers.
@nl
P2093
P1433
P1476
PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers.
@en
P2093
Christoph Lengauer
Frank Stegmeier
Kay Xiaoqin Xiang
Marion Dorsch
William R Sellers
Yung-Mae Yao
Zainab Jagani
P304
P356
10.1158/0008-5472.CAN-08-4765
P407
P577
2009-04-28T00:00:00Z